Company: IMCR
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001671927-25-000009
Chunk: 19

Company: Immunocore Holdings plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
2)Changes in assets and liabilities:Decrease (increase) in accounts receivable836 (6,198)Increase in prepayments and other current assets(28)(1,819)Increase (decrease) in accounts payable3,342 (2,320)(Decrease) increase in accrued expenses(10,943)19,169 Increase (decrease) in operating lease liabilities756 (490)Increase in other operating assets(1,573)(1,395)Increase in other operating liabilities— 1,193 Net cash provided by (used in) operating activities435 (4,587)Cash flows from investing activitiesProceeds from sale of marketable securities10,000 — Purchase of property and equipment(298)(430)Net cash provided by (used in) investing activities9,702 (430)Cash flows from financing activitiesProceeds from exercise of share options2,551 5,754 Proceeds from issue of convertible loan notes— 402,500 Payments for debt issuance costs— (12,242)Net cash provided by financing activities2,551 396,012 Increase in net cash and cash equivalents12,688 390,995 Net foreign exchange difference on cash held8,426 (800)Cash and cash equivalents at beginning of period455,731 442,626 Cash and cash equivalents at end of period476,845 832,821 Supplemental disclosure of cash flow and non-cash informationCash (paid) received for interest, net$(5,031)$5,141 Cash paid for income taxes, net$(32)$(140)Debt issuance costs in accrued expenses and other current liabilities$— $(1,116)

The accompanying notes form an integral part of these condensed consolidated financial statements.

5

Immunocore Holdings plc

Notes to the Condensed Consolidated Financial Statements 

(Unaudited)

1. Description of business

Immunocore Holdings plc (collectively with its subsidiaries, the “Company”) is a public limited company incorporated in England and Wales and has the following wholly owned subsidiaries: Immunocore Limited, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited, Immunocore GmbH, and Immunocore Nominees Limited with operations based primarily in the United Kingdom and United States. The Company is pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. Leveraging